Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if teriflunomide will be safe and effective to
prevent relapses in patients with relapsing types of MS when switching from natalizumab to
teriflunomide in patients at risk for PML. This is a two center interventional study of
patients who have had 12 or more continuous infusions of natalizumab , who are anti-JCV-ab
positive, and who had been free of clinical relapses during prior 12 months of natalizumab
therapy who will be switching to teriflunomide.
Phase:
Phase 4
Details
Lead Sponsor:
Multiple Sclerosis Center of Northeastern New York Providence Health & Services
Collaborators:
Multiple Sclerosis Center of Northeastern New York Providence Multiple Sclerosis Center